WillItSurvive
No grouping · United States

Encore Medical, Inc.

Pre-revenue maker of transcatheter heart-defect closure devices, stuck in IPO limbo.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: IPO pricing decision or another S-1 amendment/lapse
The call

Encore Medical is a going-concern-flagged, pre-revenue device maker whose IPO has stalled for ten months while Abbott and Gore keep the US occluder market to themselves.

Encore Medical designs a medical device to close a specific type of heart defect (ASD). The company has only 16 employees, no U.S. sales yet, and has been trying to go public since September 2025 without success. Abbott controls about 85% of this market with its Amplatzer device, and Gore also competes with a strong product, meaning Encore would have to convince doctors to switch to an unproven brand even if the device works well. The company's bank account and whether its IPO actually closes will determine if it survives long enough to even launch in the U.S. market.

Why
01
AI pressure: None apparent. AI plays no role in how occluders get implanted; Encore's own AI patient-selection license is unproven and IPO-contingent. Could AI do the core job? Unlikely.
02
Bigger players: Abbott Laboratories (Amplatzer) and W.L. Gore (Cardioform). Abbott holds roughly 85% of the ASD occluder market and Gore is a strong second, leaving little room for a pre-revenue US entrant. Could a giant copy it? Yes, easily.
03
What protects it. 35,000 CE Mark implants abroad and PERFORM IDE trial data are the only differentiators against two much larger rivals.
What would change this call
Encore's S-1 IPO actually prices and closes at $15M+ on NYSE American. Would show Encore secured capital to attempt a U.S. commercial challenge.
PERFORM IDE trial reports interim or final efficacy/safety data. Would show whether Encore's device can differentiate from Abbott/Gore in the U.S.
Next 10-K/10-Q either reiterates or lifts auditor going-concern doubt. Would show whether Encore's near-term survival risk has eased or worsened.
Key numbers
  • $2M revenue for twelve months ended Sept 30, 2025 (2025-09-30)
  • IPO terms set at $15M, $5.00/share, NYSE American (2025-12-30)
  • Six S-1 amendments filed, still 'subject to completion' (2026-07-15)
Named risks
  • Auditor-disclosed going-concern doubt about ability to continue operating. Severity: high
  • IPO stuck in registration since Sept 2025, six S-1 amendments, still unpriced July 2026. Severity: high
  • No FDA clearance for US sale, device pre-commercial pending PERFORM IDE trial. Severity: high
  • GB Sciences AI license is contingent on IPO completion and may never take effect. Severity: medium
  • Entrenched incumbents Abbott and Gore plus new entrants Occlutech and atHeart crowding market before Encore can launch. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Abbott Laboratorieslosing toAbbott held ~85% of global ASD occluder sales as of Aug 28, 2025
W.L. Gore & Associateslosing toGore Cardioform published 3-year ASSURED data (100% closure at 36mo), Aug 2025
Occlutechgaining onOcclutech recently entered the US market with a differentiated device, Aug 2025
atHeart MedicalcontestingatHeart introduced a novel occlusion approach adding competition, Aug 2025
Questions people ask
Is Encore Medical profitable in 2026?
No. Encore Medical reported FY2025 revenue of $2.58 million against a $0.92 million net loss, per a July 17, 2026 filing summary, and its auditor disclosed substantial doubt about the company's ability to continue as a going concern.
Has Encore Medical's IPO priced yet?
Not as of July 2026. Encore filed its initial S-1 on September 15, 2025 seeking $17 million, set $15 million terms in December 2025, and filed Amendment No. 6 on July 15, 2026 still marked 'Subject to Completion.'
Who is Encore Medical's biggest competitor?
Abbott Laboratories, whose Amplatzer occluder held roughly 85% of global ASD occluder sales as of an August 28, 2025 market analysis, with W.L. Gore's Cardioform device as the strong number two.
Could AI replace what Encore Medical does?
No. Encore's core product is an implantable, physician-delivered cardiac occlusion device requiring FDA clearance, which software cannot substitute for. Its June 2026 GB Sciences license only adds AI for patient selection, not the device itself.
Who owns Encore Medical?
Encore Medical is privately held and still in IPO registration as of July 2026. It was spun off from its former parent, Cardia, Inc., becoming standalone on October 1, 2020, with no confirmed prior institutional VC funding.
What is Encore Medical's IPO ticker and target raise?
Encore Medical set terms in December 2025 to raise $15 million by selling 3,000,000 shares at $5.00 each, targeting NYSE American under ticker EMI, though the offering had not closed as of July 15, 2026.
Timeline
  • 2026-07-15Amendment No. 6 to S-1 filed, still marked Subject to Completion
  • 2026-06GB Sciences AI patient-selection license signed, contingent on IPO closing
  • 2026-06Encore submitted comments to FDA's AI-enabled clinical trials pilot RFI
  • 2026-05-04Revised IPO pricing target date reported
  • 2026-04-22Estimated IPO pricing date reported
  • 2025-12-30IPO terms set: $15M raise, $5.00/share, NYSE American ticker EMI
  • 2025-09-15Initial S-1 filed seeking up to $17 million
  • 2020-10-01Began operating as standalone company after Cardia Inc spinoff
  • 2017-09-26Incorporated as a Minnesota corporation
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources